Cognition Therapeutics
CGTX
34 hedge funds and large institutions have $10.1M invested in Cognition Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
10% more funds holding
Funds holding: 31 → 34 (+3)
0.35% less ownership
Funds ownership: 32.16% → 31.81% (-0.35%)
27% less capital invested
Capital invested by funds: $13.9M → $10.1M (-$3.79M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.5M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$609K |
| 3 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$382K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$290K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$190K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$105K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$95K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$77.6K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$60.1K |
CGTX Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q4 2022, worth a combined $10.1M — down 27% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CGTX positions and 2 closed out — a net gain of 3 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $2.5M. The largest seller was P.A.W. Capital, exiting entirely with an estimated $190K sold.
- 34 institutional investors held Cognition Therapeutics (CGTX) as of Q4 2022, up from 31 in Q3 2022.
- Funds reported $10.1M of Cognition Therapeutics stock for Q4 2022, down 27% quarter-over-quarter.
- 5 funds opened new Cognition Therapeutics positions in Q4 2022 and 2 closed out, a net change of +3 holders.
- The largest Cognition Therapeutics buyer in Q4 2022 was AIGH Capital Management, an estimated $2.5M added.
- The largest Cognition Therapeutics seller in Q4 2022 was P.A.W. Capital, an estimated $190K sold.
Based on aggregated 13F filings for Q4 2022.